Search Results for "CT P6 Celltrion"

21:12 EDT 22nd May 2015 | BioPortfolio

Matching Channels


Matching News

Celltrion Healthcare Aims For IPO After FDA Green Lights Remsima

With Celltrion still awaiting the U.S. FDA's approval of its proposed biosimilar of Remicade (infliximab), its marketing subsidiary Celltrion Healthcare is aiming to launch a planned initial public of...

Celltrion expects to receive FDA nod for Remicade biosimilar this year

Celltrion announced that it plans to market Remsima, a biosimilar version of Johnson & Johnson's and Merck & Co.'s rheumatoid -More- 

Korea's Celltrion Sets Sights on U.S. Market

Celltrion, which sells a cheap version of a top-selling rheumatoid arthritis drug in Europe, is now targeting the U.S., the world’s biggest pharmaceutical market.

Celltrion presents data at US conference

Celltrion’s Remsima campaign rolled into the US this week with another presentation of data showing that the Remicade (Infliximab) biosimilar is equivalent to the reference drug.

Celltrion: Remsima could save UK, Italy and France $336m in five years

Celltrion has emphasised the savings Remsima ((inflizimab) could offer at a conference in Spain as partner Napp Pharmaceuticals prepares to extend the roll out of the Remicade biosimilar to the UK. 

Celltrion presents data showing clinical benefit of its biosimilar infliximab

Korean biopharma company Celltrion Healthcare has presented data on the clinical experience of patients…

Celltrion Announces that Remicade Biosimilar Could Save Up to $380 USD

Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease. Date:  ...

FDA delays meeting to discuss Remicade biosimilar

FDA's Arthritis Advisory Committee postponed a meeting that had been scheduled for March 17 to discuss a BLA from Celltrion Inc. (KOSDAQ:068270) for CT-P13, a biosimilar of Remicade infliximab from

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement